-
The roundtable focused on gastric cancer immunotherapy, and experts discussed the optimization of treatment processes and modes to enhance the efficiency and attenuation of immunotherapy
Time of Update: 2022-10-20
03Professor Jun Wang: Prevention-Assessment-Multidisciplinary Management-Treatment-Follow-up, Multi-link Reduction of Immunotherapy irAEsImmunotherapy is highly specific for tumor-specific antigens by stimulating a host immune response to destroy localized and metastatic cancer cells.
-
Nature subjournal: Dual-targeted CAR-NK, internal attack and external, greatly improve anti-tumor activity
Time of Update: 2022-10-20
October 12, 2022 /eMedClub News/--Over the past few years, cellular immunotherapy has emerged as a new treatment option for certain types of hematologic malignancies. With the entry of a number of CAR
-
100% remission rate! "Armored" oncolytic virus combined with Merck K drug to deeply explore the therapeutic potential of solid tumors
Time of Update: 2022-10-20
com——List of recent popular events——▼October 13, Sino-US Double Report Cell Bank Verification Strategy Seminar▼October 14,—— ▼October 18, the application and development trend of biopharmaceutical safety detection technologyOctober 13, 2022 / eMedClub News / -- TILT Biotherapeutics recently announced its oncolytic adenovirus candidate TILT-123 Completed the first phase 1 clinical dosing with Merck PD-1 monoclonal antibody KEYTRUDA (pembrolizumab) for the treatment of platinum-resistant or refractory ovarian cancer patients.
-
Targeting another undruggable KRAS mutant, Mirati's targeted anti-cancer therapy was published in the Nature sub-issue
Time of Update: 2022-10-20
▲If you have any business needs, please long press to scan the QR code above, orand the crystal structure bound to KRAS G12D (Image source: Reference [1])The researchers tested the anticancer activity of MRTX1133 in a series of tumor models of human cell line transplantation or patient tissue transplantation that carry the KRAS G12D gene mutation.
-
The G-based chemotherapy-free regimen | the literature of QunYinghui No. 13 brings new ideas for the treatment of indolent lymphoma
Time of Update: 2022-10-20
Literature Intensive Reading (1)Use of GALEN-free chemotherapy regimens in the first-line treatment of FLProfessor Wei Wei shared a paper published by Blood titled "Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA.
-
Inceptor introduces new non-viral transduction technology to help CAR-T fight solid tumors, what is the progress of solid tumor cell therapy in China?
Time of Update: 2022-10-20
, Ltd. was declared for clinical trial, according to the official website of Pricewatercell, the product is a solid tumor RAK cell therapy, RAK cells are a class of cells with anti-tumor activity obtained after cytokines are induced in vitro and expanded in large quantities, with strong anti-tumor killing ability and non-restrictive tumor 。➤ ➤ On September 6, 2022, the clinical trial application of "KQ-L6 autologous chimeric antigen receptor T cell injection" of Shanghai Keqi Pharmaceutical Technology Co.
-
Risk factors for recurrence of orbital meningioma and coping strategies
Time of Update: 2022-10-20
Epub 2022 Feb 26】 Research background Spheno-orbital meningiomas (SOM) often spread along surrounding structures, invading the sphenoid, orbit and dura, and even growing into the orbital apex, optic tube, and supraorbital fissure.
-
Allogene: Developed universal CAR-T with the help of oncologists across the United States
Time of Update: 2022-10-20
544px;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;margin-bottom: 0px;">——List of recent popular events——▼October 13, Sino-US Double Report Cell Bank Verification Strategy Seminar▼October 14,—— ▼October 18, the application and development trend of biopharmaceutical safety detection technologyOctober 13, 2022 /eMedClub News/-CAR-T therapy is a breakthrough treatment that has been a boon to many oncology patients, but its pricing and preparation process have significantly limited accessibility.
-
【JCO】59 hospitals participated in the trial! Professor Wang Jie's team at the Chinese Academy of Medical Sciences has discovered a new treatment strategy for non-small cell lung cancer
Time of Update: 2022-10-20
The study investigated the efficacy and safety of Torpalimab (tolipalimab) combination chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
The study investigated the efficacy and safety of Torpalimab (tolipalimab) combination chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC).
-
Professor Chen Rong: Survival status of young breast cancer patients and choice of fertility timing
Time of Update: 2022-10-20
In short, for young breast cancer patients, after the primary disease treatment is satisfactory, fertility can be considered, but it must be after chemotherapy is completed, and do not try to get pregnant during adjuvant endocrine therapy.
-
Nat Chem Biol Small Molecules Targeting Biomolecular Agglomerates: Jidong Zhu/Guangya Zhu team discovered a new strategy for targeting AR phase separation for prostate cancer
Time of Update: 2022-10-20
Since AR promotes its transcriptional activity through NTD-mediated phase separation, the authors hope to inhibit the transcriptional activity of AR through liquid-liquid phase separation of small molecules targeting AR and overcome the problem of resistance to AR antagonist drugs caused by mutations or deletions of LBD(Figure 3).
-
Clin Cancer Res: AZD4635 is well tolerated in solid tumors as monotherapy or in combination with duvalumab
Time of Update: 2022-10-20
Download the Doctor Station App and subscribe anytime, anywhere~▎▎▎▎▎▎▎▎Clinical problems:The safety of AZD4635 monotherapy or in combination with duvalumab in solid tumors is unclear.
CCR-22-0612/709575/Phase-Ia-b-Open-Label-Multicenter-Study-of-AZD4635 The top journal essentials assistant for staring at clinical literature is online 👇1.
-
ESMO Reviews & i Hope Time The Chinese innovative drug suvotinib brings new hope to EGFR exon20ins NSCLC patients
Time of Update: 2022-10-20
Suvotenib (DZD9008, sunvozertinib) is the first and only domestic "class I new drug" in the field of lung cancer that has obtained "breakthrough therapy designation (abbreviation: BTD)" in China and t
-
JAMA (IF=157) Cheng Ying and other teams from Jilin Provincial Cancer Hospital found effective immunotherapy for small cell lung cancer: domestic PD-1 fills the gap in the first-line treatment of small cell lung cancer
Time of Update: 2022-10-20
On September 27, 2022, Cheng Ying's team at Jilin Provincial Cancer Hospital published an online publication in the Journal of the American Medical Association, one of the world's top four medical journals Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients with Extensive-Stage Small Cell Lung Cancer", which confirms that serplulimab () compared with chemotherapy alone Serplulimab) in combination with chemotherapy resulted in a significant improvement in overall survival (median overall survival of 15.
-
p53 drugs in cancer: one protein, multiple targets
Time of Update: 2022-10-20
In 2002, chemical drug screening found that PRIMA-1 (p53 reactivation induces mass apoptosis1), a compound that restores wtp53 function after binding to mutp53, triggers apoptosis in vitro in transducing Saos-2 cells expressing the R273H mutant protein (p53 (R273H)) and inhibits tumor formation in vivo through these cells 。 Like PRIMA-1, MIRA-1 and STIMA-1 also have Michael receptor activity and can potentially modify cysteine in the p53 protein to stabilize wild-type conformations and prevent mutp53 from unfolding.
-
J Clin Oncol: Efficacy and safety of the FGFR1-4 inhibitor Rogaratinib in advanced urothelial carcinoma
Time of Update: 2022-10-19
This is a randomized, open-label phase II/III trial in which patients with locally advanced or metastatic urothelial carcinoma who had previously received ≥-line platinum-containing regimen were randomized (1:1) to receive either Rokaratinib (800 mg orally, twice daily, n=87) or chemotherapy (docetaxel 75 mg/m2, paclitaxel 175 mg/m2, or vinflunine 320 mg/m2, n=88) 。 The primary endpoints were overall survival and objective response rate.
-
Cell: Army Military Medical University found the presence of tumor antigen-specific memory CD8+ T cells in tumor draining lymph nodes
Time of Update: 2022-10-19
。Original link: On October 7, 2022, the international top journal "Cell" published online the important research results completed by the team of Ye Lilin/Xu Lifan and collaborators of the Department of Immunology, School of Basic Medical University of Army Medical University, "The. primordial.
-
Can ACE inhibitors/ARB antihypertensive drugs prevent cardiotoxicity caused by chemotherapy in early breast cancer?
Time of Update: 2022-10-19
A meta-analysis published in the journal Transl Cancer Res evaluated the effect of ACE inhibitors/ARBs on cardiotoxicity induced by anthracycline chemotherapy with or without trastuzumab in patients with early-stage breast cancer。 ACEI and ARB have a definite antihypertensive effect, especially in patients with heart failure, myocardial infarction, diabetes, and chronic kidney disease, and there is sufficient evidence to improve prognosis.
-
JAMA Surg: A long-term prognostic study of minimally invasive breast surgery in patients with early-stage breast cancer
Time of Update: 2022-10-19
The results showed no significant difference between groups in the main endpoint parameters: 10-year local recurrence-free survival (93.
The results showed no significant difference between groups in the main endpoint parameters: 10-year local recurrence-free survival (93.
-
Radiology: Histopathological value of a deep learning survival prediction model for chest CT in lung adenocarcinoma patients
Time of Update: 2022-10-19
Recently, a study published in the journal Radiology evaluated the association between features extracted from DL survival prediction models and histopathological risk factors by using unsupervised clustering studies, and analyzed the value of these correlations through a series of regression analyses, providing a reference for clinical accurate assessment of the prognosis of lung cancer patients.
